{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:03:22Z","timestamp":1767211402093,"version":"3.46.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010956","name":"SUNY Upstate Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ucl.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:23:24Z","timestamp":1761654204000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Genetic Testing in Localized Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Rebecca A.","family":"Sager","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennady","family":"Bratslavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.007_bib2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/cncr.11262","article-title":"Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis","volume":"97","author":"Zeegers","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.007_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","article-title":"Hereditary prostate cancer: epidemiologic and clinical features","volume":"150","author":"Carter","year":"1993","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.007_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrurol.2014.91","article-title":"Prostate cancer in young men: an important clinical entity","volume":"11","author":"Salinas","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"Cell"},{"issue":"7637","key":"10.1016\/j.ucl.2025.09.007_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.007_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.007_bib9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.007_bib10","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/sj.bjc.6604132","article-title":"Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype","volume":"98","author":"Mitra","year":"2008","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2025.09.007_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djm005","article-title":"Prostate cancer progression and survival in BRCA2 mutation carriers","volume":"99","author":"Tryggvadottir","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.007_bib12","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.ucl.2025.09.007_bib13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/pros.23204","article-title":"Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers","volume":"76","author":"Gleicher","year":"2016","journal-title":"Prostate"},{"issue":"18","key":"10.1016\/j.ucl.2025.09.007_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.007_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.007_bib16","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s13277-013-1157-5","article-title":"G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis","volume":"35","author":"Huang","year":"2014","journal-title":"Tumour Biol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.007_bib17","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/1055-9965.EPI-09-0058","article-title":"Germ-line mutations in mismatch repair genes associated with prostate cancer","volume":"18","author":"Grindedal","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"15_suppl","key":"10.1016\/j.ucl.2025.09.007_bib18","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1200\/JCO.2018.36.15_suppl.5036","article-title":"Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Smits","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ucl.2025.09.007_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.04.016","article-title":"Efficacy of Anti-PD-(L)1 immunotherapy in patients with DNA mismatch repair-deficient metastatic castration-resistant prostate cancer","author":"van Wilpe","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2025.09.007_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/JU.0000000000000137","article-title":"Bringing prostate cancer germline genetics into clinical practice","volume":"202","author":"Das","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J Clin Investig"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.007_bib24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.007_bib25","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.007_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.ucl.2025.09.007_bib27","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ucl.2025.09.007_bib28","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","article-title":"Role of genetic testing for inherited prostate cancer risk: philadelphia prostate cancer consensus conference 2017","volume":"36","author":"Giri","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.007_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines(R) insights: prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"10.1016\/j.ucl.2025.09.007_bib31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines(R) insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.007_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib33","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-Gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib34","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41391-021-00428-y","article-title":"Impact of decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative","volume":"25","author":"Vince","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"10.1016\/j.ucl.2025.09.007_bib35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1200\/JCO.2014.59.0026","article-title":"Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy","volume":"33","author":"Den","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2014.11.030","article-title":"A Biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer","volume":"68","author":"Cullen","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib37","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12885-024-12389-1","article-title":"Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis","volume":"24","author":"Cui","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2017.09.013","article-title":"A biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease","volume":"73","author":"Van Den Eeden","year":"2018","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.ucl.2025.09.007_bib39","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1200\/JCO.19.02267","article-title":"17-gene genomic prostate score test results in the canary prostate active surveillance study (PASS) cohort","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2025.09.007_bib40","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","article-title":"Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort","volume":"31","author":"Cooperberg","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41391-019-0159-9","article-title":"Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy","volume":"23","author":"Canter","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.007_bib42","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2015.223","article-title":"Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","volume":"113","author":"Cuzick","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41391-023-00766-z","article-title":"Genomic classifiers and prognosis of localized prostate cancer: a systematic review","volume":"28","author":"Boyer","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.ucl.2025.09.007_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00345-021-03622-8","article-title":"Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes","volume":"40","author":"Walker","year":"2022","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.09.007_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41585-019-0164-8","article-title":"The influence of BRCA2 mutation on localized prostate cancer","volume":"16","author":"Taylor","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"33","key":"10.1016\/j.ucl.2025.09.007_bib46","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2025.09.007_bib47","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2025.09.007_bib48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.09.007_bib49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.ucl.2025.09.007_bib50","doi-asserted-by":"crossref","first-page":"TPS285","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS285","volume":"40","author":"Kibel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.007_bib51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.eururo.2021.03.031","article-title":"Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer","volume":"80","author":"Berchuck","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.09.007_bib52","article-title":"Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): a single-arm phase 2 study","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep Med"},{"issue":"16_suppl","key":"10.1016\/j.ucl.2025.09.007_bib53","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1200\/JCO.2025.43.16_suppl.5104","article-title":"Neoadjuvant niraparib in men with DNA repair gene deficient clinically localized prostate cancer: clinical and molecular results from a phase 2 investigator-initiated trial","volume":"43","author":"Dall\u2019Era","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:04:48Z","timestamp":1765289088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0094014325000904"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.007","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Genetic Testing in Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}